Sone-Ve Delivers Phase III Gastric Cancer Win, Marking First Success for AstraZeneca's Wholly Owned ADC Portfolio
AZN sits 28% above its 52-week low of $134.9.
Summary
AstraZeneca's wholly owned ADC Sone-Ve met its primary overall survival endpoint in a Phase III trial for advanced gastric cancer, marking the first win for its in-house ADC pipeline and a potential new standard of care for a broad patient group.
Key Events · Product Development and Regulatory · AZN
-
Phase III OS Win for Sone-Ve
Sonesitatug vedotin met the dual primary endpoint of overall survival in 3rd and later-line treatment and a key secondary endpoint of OS in the overall 2nd and later-line population in CLDN18.2-positive advanced gastric/GEJ cancers.
-
First Wholly Owned ADC Readout
This is the first pivotal readout from AstraZeneca's wholly owned ADC portfolio, validating its internal ADC platform beyond partnered assets like Enhertu.
-
Broad Patient Opportunity
The trial used a ≥25% CLDN18.2 expression cutoff, covering approximately 60% of gastric/GEJ cancer patients, significantly expanding the addressable population versus higher cutoffs.
-
PFS Trend, Not Significant
The other dual primary endpoint of progression-free survival showed a trend toward improvement but did not reach statistical significance, a minor negative that does not overshadow the OS benefit.
Analysis · AZN · Life Sciences
Sonesitatug vedotin (Sone-Ve) delivered a statistically significant and highly clinically meaningful improvement in overall survival for patients with 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers. This is the first Phase III trial to demonstrate an OS benefit with an anti-CLDN18.2 ADC, and it represents the first pivotal readout from AstraZeneca's wholly owned ADC portfolio. The results position Sone-Ve as a potential new standard of care for a broad patient population—approximately 60% of gastric/GEJ cancers express CLDN18.2 at the ≥25% threshold used in the trial. Given the limited treatment options and poor prognosis in this setting, a positive OS outcome marks a major clinical and commercial milestone. While the missed PFS endpoint is a minor blemish, it does not diminish the OS win, which remains the gold standard in oncology. Regulatory submissions are expected, and the data will be presented at a forthcoming medical meeting.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 40.7% of the 388 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $172.28 on NYSE in the Life Sciences sector, with a market capitalization of approximately $262.5B. The 52-week trading range was $134.90 to $212.71. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.